Updated
The most significant concentration Kestra Medical Technologies, Lt discloses is ASSURE WCD, classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: Kestra Medical Technologies, Lt’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
“10-K Item 1A: 'We generate revenue primarily from the lease of our ASSURE WCD as part of our Cardiac Recovery System platform, and we are therefore highly dependent on our ASSURE WCD for our continued success.'”
“10-K Item 1A: 'our inability to obtain sufficient and timely supplies of components necessary to manufacture our products or secure second source suppliers if our primary suppliers are unable to fulfill our orders'”
Kestra Medical Technologies' concentration risk is concentrated in two high-share exposures, one structural and one a supply dependency. The company generates revenue primarily from the lease of its ASSURE WCD as part of its Cardiac Recovery System platform, and states it is therefore highly dependent on the ASSURE WCD for its continued success — a high-share, structural concentration in a single product line rather than a diversified device portfolio. Compounding this, the company discloses an inability to obtain sufficient and timely supplies of components necessary to manufacture its products, or to secure second-source suppliers if its primary suppliers are unable to fulfill orders, a high-share dependency on the supply side. These two exposures reinforce one another: because ASSURE WCD is effectively the whole business, any disruption to the primary suppliers that manufacture its components would directly threaten the company's only meaningful revenue stream, with no disclosed second product line to absorb the impact and no confirmed second-source supplier to fall back on. For a name this concentrated on a single product, the supply dependency is not a secondary risk — it is a direct threat to the structural core of the business, making both exposures effectively inseparable in practice.
For the engine’s reasoning on KMTS’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| ANGO | AngioDynamics, Inc. | 2 | 0 | 0 | 2 |
| KMTS● | Kestra Medical Technologies, Lt | 2 | 0 | 0 | 2 |
| ATRC | AtriCure, Inc. | 1 | 1 | 1 | 3 |
| ATR | AptarGroup, Inc. | 1 | 1 | 0 | 2 |
| ALGN | Align Technology, Inc. | 1 | 0 | 0 | 1 |
| AVTR | Avantor, Inc. | 1 | 0 | 0 | 1 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.